AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24621304 — intervention group
Group type: EXPERIMENTAL
Intervention: Bibliotherapy (self-help manual)
Number of subjects: 56
Study 24621304 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 56
Study 23557253 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-oriented play group
Number of subjects: 186
Study 23557253 — intervention group
Group type: EXPERIMENTAL
Intervention: Play-as-usual group
Number of subjects: 186
Study 23557253 — intervention group
Group type: COMPARATOR
Intervention: Historical community control group
Number of subjects: 186
Study 21402295 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 104
Study 21402295 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitors (PPI)
Number of subjects: 104
Study 17962050 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (500mg capsules twice a day for 3 months)
Number of subjects: 509
Study 17962050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 509
Study 20380782 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 318
Study 20380782 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI) pharmacotherapy
Number of subjects: 318
Study 20380782 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (IPT or SSRI)
Number of subjects: 318
Study 16060712 — intervention group
Group type: EXPERIMENTAL
Intervention: tretinoin emollient cream 0.05%
Number of subjects: 204
Study 16060712 — intervention group
Group type: COMPARATOR
Intervention: placebo (vehicle emollient cream)
Number of subjects: 204
Study 11967600 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical incidents (CIs) related to mechanical ventilation
Number of subjects: 137
Study 11967600 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-life-threatening CIs
Number of subjects: 137
Study 11967600 — intervention group
Group type: EXPERIMENTAL
Intervention: Life-threatening CIs
Number of subjects: 137
Study 11967600 — intervention group
Group type: EXPERIMENTAL
Intervention: CI reporting method
Number of subjects: 137
Study 9669456 — intervention group
Group type: EXPERIMENTAL
Intervention: Superlux Molar
Number of subjects: 95
Study 9669456 — intervention group
Group type: COMPARATOR
Intervention: P‐50 APC
Number of subjects: 95
Study 7822066 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg taken four times daily)
Number of subjects: 12
Study 7822066 — intervention group
Group type: COMPARATOR
Intervention: Control (no spironolactone)
Number of subjects: 12
Study 7822066 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone and Control
Number of subjects: 12
Study 2907849 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotherapy (group 1, n = 8)
Number of subjects: 14
Study 2907849 — intervention group
Group type: COMPARATOR
Intervention: Combined cyclophosphamide and steroids (group 2, n = 6)
Number of subjects: 14
Study 11927734 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART regimen including d4T, 3TC, nevirapine, ritonavir, and nelfinavir
Number of subjects: 193
Study 11927734 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T
Number of subjects: 193
Study 11927734 — intervention group
Group type: EXPERIMENTAL
Intervention: 3TC
Number of subjects: 193
Study 11927734 — intervention group
Group type: EXPERIMENTAL
Intervention: nevirapine
Number of subjects: 193
Study 11927734 — intervention group
Group type: EXPERIMENTAL
Intervention: ritonavir
Number of subjects: 193
Study 11927734 — intervention group
Group type: EXPERIMENTAL
Intervention: nelfinavir
Number of subjects: 193
Study 29856651 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise with low repetitions
Number of subjects: 13
Study 29856651 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity exercise with moderate repetitions
Number of subjects: 13
Study 29856651 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity exercise with high repetitions
Number of subjects: 13
Study 26684607 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole (372 mg prodrug; equivalent to 200 mg isavuconazole; intravenously three times a day on days 1 and 2, then either intravenously or orally once daily)
Number of subjects: 527
Study 26684607 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole (6 mg/kg intravenously twice daily on day 1, 4 mg/kg intravenously twice daily on day 2, then intravenously 4 mg/kg twice daily or orally 200 mg twice daily from day 3 onwards)
Number of subjects: 527
Study 26684607 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Number of subjects: 527
Study 26684607 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole
Number of subjects: 527
Study 24906392 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving guided self-help intervention
Number of subjects: 124
Study 24906392 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 124
Study 22956707 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored multifaceted intervention program combining professional, organizational, and patient-directed activities, including educational training for general practitioners and support visits by a trained facilitator, tailored to participants' needs and attitudes.
Number of subjects: 712
Study 22956707 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 712
Study 22956707 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 712
Study 18486287 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended midwifery support (EMS)
Number of subjects: 849
Study 18486287 — intervention group
Group type: COMPARATOR
Intervention: Standard postnatal midwifery support (SMS)
Number of subjects: 849
Study 18520677 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-initiated HIV counseling and testing
Number of subjects: 754
Study 18520677 — intervention group
Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 754
Study 16276136 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (mean dose of 1.8+/−1.1 mg/kg/min for 5.5+/−3.9 days)
Number of subjects: 23
Study 16276136 — intervention group
Group type: COMPARATOR
Intervention: Historical control (no direct thrombin inhibitors)
Number of subjects: 23
Study 12362931 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (800 mg per day)
Number of subjects: 9
Study 12362931 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (400 mg per day)
Number of subjects: 9
Study 12362931 — intervention group
Group type: COMPARATOR
Intervention: Digoxin alone
Number of subjects: 9
Study 10022702 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Number of subjects: 1557
Study 7790637 — intervention group
Group type: EXPERIMENTAL
Intervention: High PerAb students
Number of subjects: 51
Study 7790637 — intervention group
Group type: COMPARATOR
Intervention: Low PerAb students
Number of subjects: 51
Study 2357868 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine
Number of subjects: 57
Study 2357868 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 57
Study 2357868 — intervention group
Group type: COMPARATOR
Intervention: No gum
Number of subjects: 57
Study 77763 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (3 oz.)
Number of subjects: 31
Study 77763 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg)
Number of subjects: 31
Study 77763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 31346969 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 300,000 IU; n=46
Number of subjects: 100
Study 31346969 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with vitamin D 300,000 IU; n=46
Number of subjects: 100
Study 28515110 — intervention group
Group type: EXPERIMENTAL
Intervention: Biennial FIT screening for women
Number of subjects: 480
Study 28515110 — intervention group
Group type: EXPERIMENTAL
Intervention: Biennial FIT screening for men
Number of subjects: 480
Study 28515110 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual FIT screening for women
Number of subjects: 480
Study 28515110 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual FIT screening for men
Number of subjects: 480
Study 28515110 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal gender-based screening
Number of subjects: 480
Study 28515110 — intervention group
Group type: COMPARATOR
Intervention: Optimal uniform screening
Number of subjects: 480
Study 26362690 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 90
Study 26362690 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 90
Study 26362690 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based walking
Number of subjects: 90
Study 23941026 — intervention group
Group type: EXPERIMENTAL
Intervention: Planas Direct Tracks (PDT)
Number of subjects: 40
Study 23941026 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 21749928 — intervention group
Group type: EXPERIMENTAL
Intervention: Resurfacing total hip arthroplasty (R-THA)
Number of subjects: 43
Study 21749928 — intervention group
Group type: COMPARATOR
Intervention: Standard total hip arthroplasty (S-THA)
Number of subjects: 43
Study 21749928 — intervention group
Group type: EXPERIMENTAL
Intervention: Both R-THA and S-THA
Number of subjects: 43
Study 20144167 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of the peritoneum
Number of subjects: 533
Study 20144167 — intervention group
Group type: COMPARATOR
Intervention: Non-closure of the peritoneum
Number of subjects: 533
Study 17076758 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.6 mg/kg
Number of subjects: 73
Study 17076758 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg
Number of subjects: 73
Study 17076758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 12747344 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pentazocine (100 mg) plus lorazepam (1 mg)
Number of subjects: 100
Study 12747344 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine (30 mg) plus lorazepam (1 mg)
Number of subjects: 100
Study 11933363 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptic dressing
Number of subjects: 99
Study 11933363 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepitel dressing
Number of subjects: 99
Study 11933363 — intervention group
Group type: COMPARATOR
Intervention: Jelonet dressing
Number of subjects: 99
Study 8983584 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour Doppler ultrasound
Number of subjects: 73
Study 1619098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) with therapeutic empathy
Number of subjects: 185
Study 1619098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) with homework compliance
Number of subjects: 185
Study 1619098 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients of novice therapists
Number of subjects: 185
Study 1619098 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who terminated therapy prematurely
Number of subjects: 185
Study 1619098 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with borderline personality disorder
Number of subjects: 185
Study 6532143 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol preload
Number of subjects: 0
Study 6532143 — intervention group
Group type: COMPARATOR
Intervention: No alcohol preload
Number of subjects: 0
Study 30457088 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever camp (FC) plus durable wall lining (DWL) with deltamethrin
Number of subjects: 0
Study 30457088 — intervention group
Group type: COMPARATOR
Intervention: No kala‐azar transmission activity (IRS with deltamethrin, larvicide with temephos, house-to-house search)
Number of subjects: 0
Study 30457088 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever camp (FC) plus insecticide (deltamethrin) impregnated bed-nets (ITN)
Number of subjects: 0
Study 29401473 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing of positive emotions for 20 minutes daily for 30 days
Number of subjects: 75
Study 29401473 — intervention group
Group type: COMPARATOR
Intervention: Control group writing daily events for 30 days
Number of subjects: 75
Study 26202039 — intervention group
Group type: EXPERIMENTAL
Intervention: Worker and Workplace Package (WWP)
Number of subjects: 0
Study 26202039 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study 24631166 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarter zona‐pellucida (ZP) opening by laser‐assisted hatching (QLAH)
Number of subjects: 203
Study 24631166 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 203
Study 22305836 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (4 mg/d)
Number of subjects: 164
Study 22305836 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (20 mg/d)
Number of subjects: 164
Study 21198222 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading condition (participants asked to spend 20 minutes re-reading the feedback)
Number of subjects: 98
Study 21198222 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall condition (participants asked to spend 20 minutes writing down as much of the information from the feedback as they could remember)
Number of subjects: 98
Study 21198222 — intervention group
Group type: COMPARATOR
Intervention: Typical condition (participants simply sent home)
Number of subjects: 98
Study 17438220 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab (monotherapy in AFFIRM and add-on to interferon beta-1a in SENTINEL)
Number of subjects: 0
Study 17438220 — intervention group
Group type: COMPARATOR
Intervention: Control groups (non-natalizumab)
Number of subjects: 0
Study 16085513 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement, antidepressants, and psychological interventions
Number of subjects: 428
Study 16085513 — intervention group
Group type: COMPARATOR
Intervention: No history of childhood ADHD
Number of subjects: 428
Study 11811936 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐2 liposomes (12 weeks)
Number of subjects: 15
Study 11811936 — intervention group
Group type: COMPARATOR
Intervention: Placebo liposomes (12 weeks)
Number of subjects: 15
Study 9880175 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation treatment of 3 x 3.3 Gy
Number of subjects: 154
Study 9880175 — intervention group
Group type: COMPARATOR
Intervention: NSAID therapy (3 x 50 mg of diclofenac per day for 3 weeks)
Number of subjects: 154
Study 7973766 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine plus cisplatin
Number of subjects: 612
Study 7973766 — intervention group
Group type: COMPARATOR
Intervention: Vindesine plus cisplatin
Number of subjects: 612
Study 7973766 — intervention group
Group type: COMPARATOR
Intervention: Single-agent vinorelbine
Number of subjects: 612
Study 2739612 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokescreen programme
Number of subjects: 121
Study 2739612 — intervention group
Group type: COMPARATOR
Intervention: General practice antismoking advice
Number of subjects: 121
Study 1070803 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen carbon dioxide
Number of subjects: 0
Study 1070803 — intervention group
Group type: COMPARATOR
Intervention: Frigen
Number of subjects: 0
Study 30042140 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI intervention group
Number of subjects: 356
Study 30042140 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 356
Study 27687824 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive radiotherapy (RT)
Number of subjects: 124
Study 25602634 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.1%
Number of subjects: 125
Study 25602634 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nepafenac vehicle)
Number of subjects: 125
Study 24990779 — intervention group
Group type: EXPERIMENTAL
Intervention: toothpaste Mexidol Dent Fito (20 patients)
Number of subjects: 83
Study 24990779 — intervention group
Group type: EXPERIMENTAL
Intervention: mouthwash Mexidol Dent Professional (23 patients)
Number of subjects: 83
Study 24990779 — intervention group
Group type: EXPERIMENTAL
Intervention: both toothpaste and mouthwash (21 patients)
Number of subjects: 83
Study 24990779 — intervention group
Group type: COMPARATOR
Intervention: Control group (19 patients)
Number of subjects: 83
Study 22388798 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 39114
Study 22388798 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 39114
Study 22388798 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 39114
Study 22388798 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 39114
Study 19323801 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg riboflavin
Number of subjects: 123
Study 19323801 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg riboflavin
Number of subjects: 123
Study 19323801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 19323801 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin supplementation
Number of subjects: 123
Study 17689196 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of simulated bad news consultations
Number of subjects: 70
Study 15451219 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg once a day
Number of subjects: 946
Study 15451219 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg twice a day
Number of subjects: 946
Study 11376307 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oral nicorandil 3 times daily (n = 15)
Number of subjects: 30
Study 11376307 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 30
Study 9763724 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (700 mg for 5 days)
Number of subjects: 137
Study 9763724 — intervention group
Group type: COMPARATOR
Intervention: Quinine + Tetracycline (7-day regimen)
Number of subjects: 137
Study 7924750 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha (49 cases)
Number of subjects: 65
Study 7924750 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-beta (16 cases)
Number of subjects: 65
Study 7924750 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN treatment
Number of subjects: 65
Study 3047220 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate emulsion (1 g four times daily)
Number of subjects: 97
Study 3047220 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 97
Study 2035471 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg beta-carotene per day
Number of subjects: 582
Study 766573 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based system for detecting ventricular arrhythmias
Number of subjects: 15
Study 31596415 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol chewing gum
Number of subjects: 102
Study 31596415 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 102
Study 27530529 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual education plus self-care instruction for symptoms and quality of life issues, communication coaching, and symptom tracking
Number of subjects: 0
Study 27530529 — intervention group
Group type: COMPARATOR
Intervention: Usual education about symptoms and quality of life topics
Number of subjects: 0
Study 26515686 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 quantification by MRI
Number of subjects: 190
Study 23642641 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile massage (TM)
Number of subjects: 46
Study 23642641 — intervention group
Group type: COMPARATOR
Intervention: Relaxation exercises
Number of subjects: 46
Study 21663425 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (2-15 mg/day)
Number of subjects: 330
Study 21663425 — intervention group
Group type: COMPARATOR
Intervention: Prior placebo
Number of subjects: 330
Study 21663425 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior aripiprazole
Number of subjects: 330
Study 21663425 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 330
Study 19252247 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0
Study 19252247 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 19252247 — intervention group
Group type: COMPARATOR
Intervention: TNF inhibitors
Number of subjects: 0
Study 18001541 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (UTI) treatment in Group A
Number of subjects: 30
Study 18001541 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (UTI) treatment in Group C
Number of subjects: 30
Study 15112008 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% suspension concentrate (SC) deltamethrin applied with manual compression sprayers
Number of subjects: 667
Study 15112008 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% suspension concentrate (SC) deltamethrin applied with power sprayers
Number of subjects: 667
Study 15112008 — intervention group
Group type: COMPARATOR
Intervention: 1.5% emulsifiable concentrate (EC) deltamethrin
Number of subjects: 667
Study 15112008 — intervention group
Group type: COMPARATOR
Intervention: 10% EC cis-permethrin
Number of subjects: 667
Study 11215604 — intervention group
Group type: EXPERIMENTAL
Intervention: DE CL group
Number of subjects: 58
Study 11215604 — intervention group
Group type: EXPERIMENTAL
Intervention: CL group
Number of subjects: 58
Study 11215604 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 9728566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 12
Study 9728566 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 12
Study 7844976 — intervention group
Group type: EXPERIMENTAL
Intervention: Live workshop training
Number of subjects: 0
Study 7844976 — intervention group
Group type: COMPARATOR
Intervention: Video training
Number of subjects: 0
Study 3128100 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (800 IU/d for 5 weeks)
Number of subjects: 20
Study 3128100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20